Collectively, CREB1-EZH2-TSP axis is inevitably involved in the regulation of NE phenotype in prostate cancer progression, which guide a potential determinant for therapeutic strategy in NEPC patients. The gene discussed is EZH2; the disease is prostate carcinoma.